German Market Access – Simplified
Everything you need to know in one place, explained in simple terms
Here are the latest G-BA decisions from the G-BA meeting held on 6 February 2025 on the early benefit assessments of Filspari, Livmarli, Dupixent, Tagrisso, Rozlytrek, and Kigabeq. A complete database of all previous G-BA resolutions is in my membership. Filspari (sparsentan) immunoglobulin A – nephropathy, primary – Orphan drug, Hint of minor additional benefit Livmarli (maralixibat); new…
Here are the latest G-BA decisions from the G-BA meeting held on 19 Dec 2024 on the early benefit assessments of Tagrisso, Yescarta, Qalsody, Fabhalta, Opdivo, and Trimbow. A complete database of all previous G-BA resolutions is in my membership. Tagrisso (osimertinib); re-assessment after expiry of previous decision: non-small cell lung cancer, EGFR mutations, adjuvant therapy…
Here are the latest G-BA decisions from the G-BA meeting held on 5 Dec 2024 on the early benefit assessments of Exblifep and the requirement of RWE collection for marstacimab. A complete database of all previous G-BA resolutions is in my membership. Exblifep (cefepime/enmetazobactam); bacterial infections, multiple indications – Reserve antibiotic; Additional benefit deemed proven across all…
Here are the latest G-BA decisions from the G-BA meeting held on 2 Oct 2024 on the early benefit assessments of Velsipity, Eladynos, Altuvoct and Ryzneuta. A complete database of all previous G-BA resolutions is in my membership. This time, the G-BA met on a Wednesday and made the following decisions. Interestingly, for two products,…
Here are the latest G-BA decisions from the G-BA meeting held on 19 Sep 2024 on the early benefit assessments of Skyclaris, Vyvgart, Abecma, Imfinzi, Evrysdi and Elucirem. A complete database of all previous G-BA resolutions is available upon request. This time, the G-BA decisions include the assessment of the diagnostic agent Elucirem, which unsurprisingly…
Here are the latest G-BA decisions from the G-BA meeting held on 15 Aug 2024 on the early benefit assessments of Rystiggo, Omjjara, Talzenna, Quviviq, Beyfortus, Zilbrysq, Aqumeldi, and Inaqovi. A complete database of all previous G-BA resolutions is available upon request. Good results for orphan drugs, but negative for all other assessed drugs. Rystiggo (rozanolixizumab);…
Here are the latest G-BA decisions from the G-BA meeting held on 1 Aug 2024 on the early benefit assessments of Rezzayo, Briumvi, Veoza, Veltassa, and Vanflyta. A complete database of all previous G-BA resolutions is available upon request. Rezzayo (rezafungin) invasive Candida infections – Orphan drug, Hint of not-quantifiable additional benefit Briumvi (ublituximab); relapsing-remitting multiple sclerosis -…
Here are the latest G-BA decisions from the G-BA meeting held on 4 July 2024, which covered only procedural decisions. A complete database of all previous G-BA resolutions is available upon request. Opdivo (nivolumab): melanoma (stage IIB or IIC), adjuvant therapy, ≥ 12 years, monotherapy – Removal of time restriction of previous decision Carvykti (ciltacabtagene autoleucel): multiple myeloma)…
Here are the G-BA decisions from the G-BA meeting held on 4 July 2024 on the early benefit assessments of Agamree, Loargys, Elrexfio, Evkeeza, and Ondexxya. A complete database of all previous G-BA resolutions is available upon request. Agamree (vamorolone); Duchenne muscular dystrophy, ≥ 4 years – Orphan drug, Hint of not-quantifiable additional benefit Loargys (pegzilarginase); hyperargininemia (ARG1-D),…
Here are the G-BA decisions from the G-BA meeting held on 20 June 2024 on the early benefit assessments of Jemperli, Ayvakyt, Keytruda, Polivy, Yorvipath, Jardiance, and Libmeldy. There was the rare occurrence of a major additional benefit – this is only the 12th time this highest rating was awarded. A complete database of all previous G-BA…